Related Experiment Video
Updated: Aug 14, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Aspirin, warfarin and a thienopyridine for acute coronary syndromes
Yuval Konstantino1, Zaza Iakobishvili, Avital Porter
1Department of Cardiology, Rabin Medical Center, Petah-Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Insights
Triple therapy (TT) using warfarin alongside dual therapy (DT) in acute coronary syndrome (ACS) patients is feasible. While TT patients experienced more bleeding events, adjusted mortality rates at 30 days and 6 months were similar between groups.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Dual therapy (DT) with clopidogrel and aspirin is standard for acute coronary syndrome (ACS).
- Triple therapy (TT), involving warfarin in addition to DT, is sometimes necessary for specific ACS patient populations.
Purpose of the Study:
- To investigate the incidence, complications, and outcomes associated with triple therapy (TT) in ACS patients.
- To compare the safety and efficacy of TT versus DT in the management of ACS.
Main Methods:
- Analysis of Israeli national surveys data for ACS patients from 2000 to 2004.
- Comparison of patient demographics, treatment protocols, and clinical outcomes between TT and DT groups.
Main Results:
- Triple therapy (TT) was administered to 1.3% of ACS patients (n=76), who were older and had more prior cardiac disease.
- TT patients experienced higher rates of heart failure, arrhythmias, ischemia, and major bleeding (2.6% vs. 0.6%, p=0.03) during hospitalization.
- No significant differences in adjusted 30-day and 6-month mortality were observed between the TT and DT groups.
Conclusions:
- Triple therapy (TT) is a feasible treatment option for ACS patients requiring concurrent warfarin therapy.
- Careful monitoring for complications, particularly bleeding, is essential in ACS patients undergoing TT.
Background:
Although clopidogrel and aspirin (dual therapy, DT) are used for acute coronary syndrome (ACS), sometimes treatment with warfarin (triple therapy, TT) is required.
Aim:
To determine the incidence, complications, and outcomes of TT.
Methods:
We analyzed Israeli surveys of ACS from 2000 to 2004.
Results:
In these surveys, 5,706 (96%) were discharged alive from hospital. Post-ACS TT and DT were 76 patients (1.3%) and 2,661 patients (46.7%), respectively. The TT group was older with more prior cardiac disease. During hospitalization, the TT patients received more intravenous anticoagulant and antithrombotic agents, and had more heart failure, arrhythmias, ischemia, and major bleeding (2.6 vs. 0.6%, p=0.03). There were no differences in adjusted 30-day and 6-month mortality between the 2 groups.
Conclusion:
TT is feasible among ACS patients who require concomitant warfarin treatment.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Acute Coronary Syndrome III: Diagnostic Studies
